Mohamed Rafiq1, Mohammed Azeemuddin1. 1. Department of Pharmacology, R&D Center, The Himalaya Drug Company, Makali, Bangalore-562123 Karnataka.
Abstract
OBJECTIVE: The present study was conducted to evaluate the efficacy of Abana® (a poly-ingredient formulation with natural constituents) on in vitro platelet aggregation and occlusion-induced deep venous thrombosis in rats. METHODS: Anti-platelet property of Abana® was evaluated using ADP (Adenosin 5-diphosphate) and adrenaline-induced platelet aggregation models, and anti-thrombotic activity was evaluated against occlusion-induced deep venous thrombosis model in wistar rats. RESULTS: Under the in vitro conditions, Abana® (250, 500 and 1000 µg/ml) alleviated ADP and adrenaline-induced platelet aggregation in a dose-dependent manner. Abana® (1000 µg/ml) inhibited ADP and adrenaline-induced platelet aggregation by as much as 50.69% and 64.83% respectively. Furthermore, 6 days pre-treatment with Abana® (250 and 500 mg/kg, p.o.) in an in vivo study showed significant and dose-dependent protection against occlusion-induced deep venous thrombosis in rats. CONCLUSION: These findings suggest that Abana®, a polyherbal formulation possesses anti-platelet and anti-thrombotic activities in the experimental models of in vitro platelet aggregation and in vivo deep venous thrombosis in rats.
OBJECTIVE: The present study was conducted to evaluate the efficacy of Abana® (a poly-ingredient formulation with natural constituents) on in vitro platelet aggregation and occlusion-induced deep venous thrombosis in rats. METHODS: Anti-platelet property of Abana® was evaluated using ADP (Adenosin 5-diphosphate) and adrenaline-induced platelet aggregation models, and anti-thrombotic activity was evaluated against occlusion-induced deep venous thrombosis model in wistar rats. RESULTS: Under the in vitro conditions, Abana® (250, 500 and 1000 µg/ml) alleviated ADP and adrenaline-induced platelet aggregation in a dose-dependent manner. Abana® (1000 µg/ml) inhibited ADP and adrenaline-induced platelet aggregation by as much as 50.69% and 64.83% respectively. Furthermore, 6 days pre-treatment with Abana® (250 and 500 mg/kg, p.o.) in an in vivo study showed significant and dose-dependent protection against occlusion-induced deep venous thrombosis in rats. CONCLUSION: These findings suggest that Abana®, a polyherbal formulation possesses anti-platelet and anti-thrombotic activities in the experimental models of in vitro platelet aggregation and in vivo deep venous thrombosis in rats.
Entities:
Keywords:
Abana®; Adrenaline-induced platelet aggregation; Anti-platelet; Anti-thrombotic; Deep venous thrombosis
Authors: Einar E Eriksson; Eva Karlof; Karin Lundmark; Pierre Rotzius; Ulf Hedin; Xun Xie Journal: Arterioscler Thromb Vasc Biol Date: 2005-01-27 Impact factor: 8.311
Authors: Chao C Chang; Wan J Lu; Cheng W Chiang; Thanasekaran Jayakumar; Eng T Ong; George Hsiao; Tsorng H Fong; Duen S Chou; Joen R Sheu Journal: J Nutr Biochem Date: 2009-12-16 Impact factor: 6.048